For canine mammary neoplasms, both Temsirolimus and Everolmius have exhibited evidence to inhibit the mTOR pathway in vitro, leading to suppressed growth of tumor-adherent cells and spheres [109]. This evidence concerns the gene MTOR and neoplasm.